Company intelligence / Profile preview
Enimmune
Taichung City, Taiwanenimmune.com.tw ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Enimmune has advanced its lead enterovirus 71 vaccine candidate ("EnVAX-A71") through Phase III and submitted NDAs in Taiwan and Macau. The company also markets approved diagnostic products such as the Tuberculin PPD RT23 SSI for tuberculosis testing and COVID antigen rapid tests. It is developing additional vaccines targeting pneumonia, norovirus, dengue fever virus, and MERS-CoV.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineMonoclonal antibodySmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
AIOS BIOTECH PTE. LTD. (Singapore) – joint venture partnerAbcombi Biosciences Inc. – pneumococcal vaccine development partnerSK Bioscience Co., Ltd., VISIONMED Co., Ltd., Inibio Co., Ltd. – exclusive distribution agreements in South Korea
Beyond the preview
Go deeper on Enimmune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enimmune.